Cardio Diagnostics (NASDAQ:CDIO) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Cardio Diagnostics (NASDAQ:CDIO – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning.

Cardio Diagnostics Stock Up 2.5%

CDIO stock opened at $3.72 on Friday. Cardio Diagnostics has a twelve month low of $3.22 and a twelve month high of $53.10. The business’s 50-day moving average price is $3.97 and its 200-day moving average price is $8.59.

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.83. Cardio Diagnostics had a negative return on equity of 76.14% and a negative net margin of 30,465.10%. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.08 million. On average, analysts expect that Cardio Diagnostics will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Two Sigma Securities LLC purchased a new position in shares of Cardio Diagnostics during the 4th quarter valued at about $48,000. Jane Street Group LLC purchased a new position in shares of Cardio Diagnostics during the 4th quarter valued at about $103,000. Millennium Management LLC purchased a new position in shares of Cardio Diagnostics during the 4th quarter valued at about $236,000. Finally, Geode Capital Management LLC raised its stake in Cardio Diagnostics by 97.6% during the 4th quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock valued at $334,000 after purchasing an additional 179,978 shares during the period. 8.06% of the stock is owned by hedge funds and other institutional investors.

Cardio Diagnostics Company Profile

(Get Free Report)

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.

See Also